StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Research analysts at StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a note issued to investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently commented on MRNS. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Royal Bank of Canada dropped their price target on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a report on Friday, October 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $4.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Marinus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Trading Down 0.2 %

MRNS opened at $0.55 on Friday. Marinus Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $10.50. The stock has a market cap of $30.32 million, a PE ratio of -0.22 and a beta of 1.03. The business’s 50 day moving average is $0.49 and its 200-day moving average is $0.85.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. World Investment Advisors LLC bought a new stake in Marinus Pharmaceuticals in the third quarter worth $104,000. Virtu Financial LLC bought a new stake in Marinus Pharmaceuticals in the fourth quarter worth $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Marinus Pharmaceuticals in the fourth quarter worth $54,000. Jacobs Levy Equity Management Inc. boosted its holdings in Marinus Pharmaceuticals by 39.5% in the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 117,255 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Marinus Pharmaceuticals by 1,968.5% in the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 126,752 shares in the last quarter. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.